Locally Advanced Rectal Cancer: Diagnosis, Staging, and Current Treatment Approaches

ContributorsProf. Dr. Mustafa ÖzdoğanAuthor · Medical review · Editorial approval

PublishedDec 9, 2025

UpdatedOct 17, 2026

15 min read

Locally Advanced Rectal Cancer: Diagnosis, Staging, and Current Treatment Approaches

In this article

SECTION 1 / 4 RECTAL ADENOCARCINOMA (2025 UPDATE)

Pretreatment Assessment and the Neoadjuvant Decision

Modern rectal cancer management relies on millimeter-level MRI staging, MRD (ctDNA) monitoring, and molecular profiling. The goal is to avoid unnecessary toxicity ("less is enough") or achieve organ preservation.

EDITORS Prof. Dr. Mustafa Özdoğan & Assoc. Prof. Dr. Atakan Demir

Editor's Note: A Shift in the Treatment Paradigm

In rectal cancer treatment, "enough is beneficial; excess is harmful" is becoming a guiding principle. Previously, every T3 tumor was considered to require neoadjuvant therapy; direct surgery has now been shown acceptable and safe in low-risk patients (upper rectum, clear MRF).

At the other end, an organ preservation revolution is occurring. Particularly in dMMR/MSI-H early-stage solid tumors and locally advanced rectal cancer, neoadjuvant PD-1 blockade (dostarlimab) has opened the possibility of cure without surgery in up to 100%. Molecular testing (MMR) is therefore vital, rather than optional.
(Ref: NEJM 2025, DOI: 10.1056/NEJMoa2404512)

1. Critical Pretreatment Assessment

Imaging & Staging

Pelvic MRI (Gold Standard)

The core of treatment planning. Axial CT is inadequate for T and N staging and should be used only for metastatic screening. The MRI report must specify these 3 parameters in millimeters:

MRF distance: Surgical margin safety.
EMVI status: Extramural venous invasion.
mrTD: Tumor deposits detected on MRI.

MRF (Mesorectal Fascia) Definitions (SAR 2023):

✅ Clear (Low Risk): Distance > 2 mm
⚠️ Threatened: Between 1 - 2 mm
⛔ Involved (High Risk): < 1 mm

Critical 2025 Update: ctDNA / MRD

ctDNA-based minimal residual disease (MRD) monitoring signals recurrence well before radiological imaging (lead time: 5.3 months). Patients who are MRD-negative after neoadjuvant therapy are ideal candidates for a watch-and-wait (organ preservation) protocol.

Molecular Profile (MANDATORY)

MMR / MSI Durumu

Assess before treatment in every rectal cancer case. It changes the treatment pathway by 100%.

dMMR / MSI-H Patients:

These patients are resistant to 5-FU-based chemoradiotherapy. Instead of standard treatment, neoadjuvant immunotherapy (dostarlimab/PD-1 blockade) may achieve complete responses approaching 100%, offering a chance of cure without surgery.

Other Markers

RAS/BRAF: For anti-EGFR treatment decisions and metastatic planning.
HER2: An emerging targeted-therapy area.

2. Who Needs Neoadjuvant Therapy? Risk Groups (2025 ESMO/NCCN)

Not all T3 tumors are the same. ESMO 2025 classifies patients as "Good," "Bad," and "Ugly" according to location (upper versus lower rectum) and MRF distance.

RISK GROUP

DEFINING CRITERIA (MRI)

TREATMENT STRATEGY

EARLY

"The Good"

• cT1-T2 or Early cT3 (cT3a/b)
• Upper rectum location (>10-12cm)
• MRF-negative: Safe margin > 2 mm (SAR 2023 Lexicon)
• cN0 (node-negative)
• EMVI and mrTD (tumor deposits) negative

*Upper rectal tumors have a lower recurrence risk because they are surrounded by peritoneum.

UPFRONT SURGERY (TME)

Neoadjuvant treatment (RT/chemotherapy) is unnecessary. TME surgery alone is sufficient.

Note: Lower rectal cT3a/b tumors (anal verge < 10cm) may shift to intermediate risk because of proximity to the sphincter.

INTERMEDIATE

"The Bad"

• cT3c/d (deep invasion > 5mm)
• Threatened MRF: Distance 1-2 mm (note: not <1mm)
• cN1-2: Limited involved lymph nodes
• EMVI / mrTD negative
• No threatened sphincter (but location < 5cm increases risk)

NEOADJUVANT CRT or CHEMOTHERAPY

Short-course RT or CRT to shrink the tumor (downstage) and secure a clear circumferential resection margin (CRM).

*New PROSPECT data support starting with FOLFOX chemotherapy alone in selected patients to avoid pelvic RT toxicity.

LOCALLY ADVANCED

"The Ugly"

• cT4 (adjacent-organ invasion)
• MRF-positive: Distance < 1 mm (resection margin considered involved)
• EMVI / mrTD positive: Increases systemic metastatic risk.
• Lateral lymph node (+): Internal iliac nodes >7mm or necrotic morphology (SAR 2023 criteria).
• Distal: < 5 cm from the anal verge (threatened sphincter)

TNT (Total Neoadjuvant Therapy)

Maximum systemic and local control (PRODIGE-23, etc.).

⚠️ Critical Warning (RAPIDO 5-Year): Long-term RAPIDO results showed significantly more local recurrence with short-course RT followed by chemotherapy (10%) than with standard CRT (6%). Use caution when selecting RAPIDO for high-risk patients.

3. Gray Areas and the 2025 Perspective

Different Approaches to cT3 N0 Tumors

The risk of understaging with EUS/MRI (unexpected node-positive disease, N+, on pathology) is approximately 17-22%. This uncertainty produces different approaches across continents:

United States (NCCN) approach:

Because of this risk, neoadjuvant treatment is recommended for almost all T3 tumors.

European (ESMO) approach:

Separates risk groups. If the tumor is in the upper rectum (anal verge >12cm), MRF >2mm, and EMVI-negative, postoperative recurrence risk is low. Direct surgery (upfront TME) is safe in this group.

Distal Tumors (< 5 cm)

Tumors within 5 cm of the anal verge usually require APR (permanent colostomy). With TNT, however, the chance of sphincter-preserving surgery now reaches 50-70%.

Goal: Life Without a Colostomy

Watch and Wait: Patients achieving a complete clinical response (cCR) may be monitored without surgery. The strongest support for this decision is MRD (ctDNA) negativity .

References and Guidelines (2025):

Hofheinz RD et al. Localised rectal cancer: ESMO Clinical Practice Guideline. Annals of Oncology 2025.
NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 3.2025.
NEJM 2025 (dMMR/Neoadjuvant PD-1 Blockade).
SAR Colorectal Lexicon 2023/2025 (MRF, EMVI, and Lateral LN Definitions).
Dijkstra EA et al. RAPIDO Trial 5-Year Follow-up. Annals of Surgery 2023 (Local Recurrence Warning).

SECTION 2 / 4

Neoadjuvant Therapy: TNT, PROSPECT, and RT Regimens

Total neoadjuvant therapy (TNT) aims for maximum control in high-risk patients, while omitting radiotherapy (PROSPECT) is being discussed for selected intermediate-risk patients.

Protocols: RAPIDO, PRODIGE-23, PROSPECT (ASCO 2024 Update), OPRA

Editor's Note: The Era of Tailored Treatment

Previously, everyone received CRT plus surgery. Today, three pathways diverge. 1) Locally advanced ("Ugly") tumors call for deploying all treatments upfront with TNT. 2) Intermediate-risk ("Bad") tumors may be carefully selected for an approach testing omission of RT to avoid toxicity—the PROSPECT model. 3) dMMR patients may receive immunotherapy without chemotherapy. This section uses algorithms to explain regimen selection for standard pMMR patients.

1. Total Neoadjuvant Therapy (TNT)

Definition: Completion of both chemotherapy and radiotherapy before planned surgery.
Goal: Eliminate micrometastases early and increase complete response (pCR) rates, opening the door to organ preservation (watch and wait).

🎯 Ideal TNT Candidates (High Risk)

Besides T4 status, the location of nodal involvement also determines the TNT decision:

cT4 (T4a/b)
Adjacent-organ invasion

MRF (+) Threat
Distance < 1 mm

EMVI (+)
Vascular invasion

Lateral lymph node (+)
Pelvic sidewall nodes (>7mm)

Extramesorectal node (+)
Obturator / External Iliac

Distal tumor
< 5cm (desire for organ preservation)

TNT Protocol Selection: RAPIDO or PRODIGE-23?

RAPIDO

Short-Course RT-Based

pCR: 28%

Protocol sequence:

RT: 5 x 5 Gy (1 week)
Waiting interval: NONE (immediate chemotherapy)
Consolidation chemotherapy: 6 cycles CAPOX or 9 cycles FOLFOX
Surgery: 2-4 weeks after chemotherapy ends

Clinical interpretation:

Radiotherapy is very brief for the patient.
⚠️ Caution: At 5-year follow-up, local recurrence was significantly higher than with long-course CRT (10% versus 6%).

PRODIGE-23

Long-Course CRT + FOLFIRINOX

pCR: 28%

Protocol sequence:

Induction chemotherapy: 6 cycles FOLFIRINOX
KRT: 50 Gy (25-28 days) + Capecitabine
Surgery: 7 weeks after CRT ends
Adjuvant: 3 months FOLFOX/Capecitabine

Clinical interpretation:

The strongest study demonstrating a disease-free survival (DFS) benefit at 7-year follow-up. Preferred in fit patients.

2. Selective CRT: PROSPECT (Careful Selection)

⚖️

Can Radiotherapy Be Omitted?

A strategy developed for intermediate-risk patients (T2N1, T3N0) to avoid radiotherapy toxicity (infertility, bowel dysfunction). It is not yet "standard treatment."

STEP 1: CHEMOTHERAPY

6 cycles mFOLFOX6 (3 months)

↓

Restaging (pelvic MRI)

More Than 20% Shrinkage

🗸

OMIT RT ➔ SURGERY

"Successful De-escalation"

Less Than 20% Shrinkage

⚠️

ADD RT ➔ SURGERY

"Return to Standard Treatment"

⚠️ Clinical Reality (2025):

Although RT omission appeared to reach 90% in PROSPECT, the rate in routine practice is around 50-60%. The 2025 NCCN and ESMO guidelines still recommend neoadjuvant CRT as the core approach for intermediate risk.

Consider RT omission (PROSPECT) through a multidisciplinary board only for patients with:

Upper-to-mid rectal location
Negative MRF and EMVI
Young age and a desire to preserve fertility
A complete/very good response to FOLFOX

3. Short-Course versus Long-Course RT

Feature	Short Course (5x5 Gy)	Long Course (50.4 Gy)
Duration and logistics	1 week. Very convenient.	5-6 weeks. Daily hospital visits.
Concurrent chemotherapy	None.	Yes (Capecitabine/5-FU), as a radiosensitizer.
Downstaging	HIGH with added consolidation chemotherapy; LOW alone.	HIGH. Standard for T4 tumors.
Preferred patient	High distant-metastasis risk and need to start chemotherapy quickly. Older/frail patients.	T4, MRF(+), distal tumors where sphincter preservation is desired.

4. Chemotherapy Regimen Selection

During CRT (Radiosensitizer)

Capecitabine: Oral, 825 mg/m² (2 times daily). Most commonly preferred.
Infusional 5-FU: A port is required. Continuous infusion at 225 mg/m².
❌ Do NOT use oxaliplatin or irinotecan concurrently with CRT.

Systemic Component of TNT

FOLFIRINOX: The most intensive and effective regimen. ECOG 0-1 (PRODIGE-23).
FOLFOX / CAPOX: Standard regimens.
Duration: Usually 3-4.5 months in total.

Key References:

PROSPECT trial (NEJM 2023 + 5-year update ASCO 2024)
NCCN Rectal Cancer Guidelines v.1.2025
ESMO Rectal Cancer Guidelines 2024/2025 update

SECTION 3 / 4

Nonoperative Management and the Immunotherapy Revolution

Strict surveillance rules for watch and wait, complete response (cCR) criteria, and the chance of cure without surgery in dMMR tumors.

Protocols: OPRA Trial, IWWD (International Watch & Wait Database), MSKCC (Dostarlimab) Focus: Organ Preservation

Editor's Note: Is Oncology Without Surgery Possible?

Rectal surgery (TME) may be oncologically curative but can impose permanent stomas, sexual dysfunction, and LARS (low anterior resection syndrome). Today, TNT (Total Neoadjuvant Therapy) has become so effective that tumors disappear completely (cCR) in 30-50% of patients.

This section examines how to safely offer patients asking "treatment is over and the tumor is gone—why have surgery?" a watch-and-wait approach , and where the remarkable 100% response in dMMR disease fits into 2025 practice.

1. Watch-and-Wait Strategy

An organ-preservation strategy using intensive surveillance instead of surgical resection when a tumor disappears completely clinically (cCR) after neoadjuvant therapy (TNT or CRT). This is an active surveillance protocol, rather than absence of treatment.

✅ Suitable Candidates

pMMR/MSS patients achieving cCR after TNT.
dMMR/MSI-H patients achieving cCR after immunotherapy.
Distal rectal tumors (strong motivation for sphincter preservation).
Requirement: Full adherence to intensive surveillance (MRI/endoscopy every 3 months for the first 2 years).

❌ Unsuitable Candidates

Chemotherapy-only patients who did not receive RT (insufficient data).
Near-cCR patients whose regression stops or whose disease progresses during observation.
Persistent MRF positivity.
Poor surveillance adherence or very high anxiety.

Complete Clinical Response (cCR) Criteria (ESMO/NCCN)

Timing is critical: assess after TNT or long-course CRT no earlier than 8 weeks, ideally after 12 weeks . Assessing too early may miss the response.

Method	Complete clinical response (cCR)	Near-complete response (near-cCR)	Incomplete response
DRE (digital rectal examination)	Flat, smooth scar. No palpable mass.	Mild induration or minor irregularity.	Palpable tumor/mass.
Endoscopy	White scar, telangiectasia. NO ulceration or nodularity.	Small mucosal nodules, superficial ulcer, mild erythema.	Visible residual tumor, deep ulcer, necrosis.
MRI (DWI)	Complete fibrosis on T2 (dark signal). NO bright signal (restriction) on DWI.	Marked regression, minimal suspicious signal within dense fibrosis.	Residual tumor signal, positive DWI restriction.

COMPLETE RESPONSE (cCR)

Criteria met

WATCH AND WAIT

NEAR-COMPLETE (near-cCR)

Minor findings remain

REASSESS AFTER 6-12 WEEKS

OPRA: 50% convert to cCR.

INCOMPLETE RESPONSE

Residual tumor

SURGERY (TME)

2. Nonoperative Surveillance Schedule

Watch and wait does not mean "treatment is over; go home." It requires active surveillance more intensive than postoperative follow-up. Of regrowths, 95% occur within the first 2 years and are intraluminal.

FIRST 2 YEARS

Every 3-4 Months: Physical examination + CEA + DRE + flexible sigmoidoscopy

Every 6 Months: Pelvic MRI (diffusion-weighted) + chest/abdominal CT

YEARS 3-5

Every 6 Months: Physical examination + CEA + DRE + sigmoidoscopy

Annually: Chest/abdominal CT

Benefits

Permanent stoma: Avoiding the risk.
No LARS: Bowel function is preserved.
Quality of life: Sexual and urinary functions remain unaffected.
Success rate: OPRA showed a 3-year organ-preservation rate of 53% with TNT.

Risks (Regrowth)

Local regrowth: Rate: 25-30%.
Timing: 95% occur within the first 2 years.
Salvage: In 90-95% of patients with regrowth, the tumor remains resectable and cure is achieved with salvage TME.

3. Immunotherapy in dMMR / MSI-H Tumors

GAME CHANGER

Dostarlimab Protocol (MSKCC)

In locally advanced dMMR rectal cancer, results from only 6 months of PD-1 blockade without chemotherapy or radiotherapy have made oncology history.

✔ Treatment: Dostarlimab 500mg (every 3 weeks for 6 months).
✔ Cercek et al. (NEJM 2022/2024): Complete clinical response in all trial participants (100%).
✔ Outcome: No patient required surgery, CRT, or chemotherapy. Minimal toxicity.

100% Complete response

⚠️ Clinical Practice Recommendation for 2025:

Before treatment in every rectal cancer patient, MMR/MSI testing is mandatory. If dMMR (5-10%) is identified, prioritize immunotherapy (dostarlimab or pembrolizumab) over standard TNT/CRT and inform the patient about this chance of "cure without surgery."

References and Scientific Sources:

OPRA Trial: Garcia-Aguilar J et al. "Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy." J Clin Oncol. 2022. (The pivotal study establishing organ-preservation rates after TNT).
MSKCC Immunotherapy Trial: Cercek A et al. "PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer." N Engl J Med. 2022; Updated ASCO 2024. (100% response rate).
IWWD Data: van der Valk MJM et al. "Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD)." Lancet. 2018.
ESMO & NCCN Guidelines (2025): Current watch-and-wait surveillance protocols and dMMR management guidelines.

SECTION 4 / 4 (FINAL)

Adjuvant Therapy and Metastatic Disease Management

Chemotherapy requirements after TNT (overtreatment risk), surgical timing for synchronous metastases, survival, and LARS management.

Concept: "The Perioperative Total of 6 Months Rule" Focus: Cure and Quality of Life

Editor's Note: When Should Treatment End?

A major current misconception is routinely giving postoperative adjuvant chemotherapy to patients who have already received 4-5 months of intensive preoperative chemotherapy through TNT (total neoadjuvant therapy).

In this final section, we apply the "enough is beneficial; excess is harmful" principle to adjuvant therapy and emphasize that molecular profiling (RAS/BRAF) is as important as surgical decisions in metastatic disease.

1. Postoperative Adjuvant Treatment Decision

Rather than surgical pathology alone, the decision depends on how much systemic therapy the patient received preoperatively (neoadjuvantly). The golden rule: Complete a total of 6 months of chemotherapy.

SCENARIO A: Patient Received TNT (RAPIDO / PRODIGE-23)

These patients have already received 18 weeks (4.5 months) of intensive chemotherapy (FOLFIRINOX or CAPOX) before surgery.

GENERAL RULE: NO ADJUVANT CHEMOTHERAPY NEEDED (Observation / Surveillance)

Exception: If neoadjuvant treatment ended early because of toxicity, the remaining duration may be completed.
ypN+ status: Persistent node positivity after TNT indicates a poor response; the benefit of giving the same drug is debatable. Observation is generally recommended.

SCENARIO B: Conventional CRT / Short Chemotherapy

If the patient received only radiotherapy with a radiosensitizer before surgery, systemic treatment remains incomplete.

ADD ADJUVANT CHEMOTHERAPY (Goal: complete a total of 6 months)

Usually, after surgery, 4 months (8 cycles) of FOLFOX or CAPOX are given.

2. Stage IV: Synchronous Metastases

Critical Rule (2025):

Before treatment decisions in metastatic disease, RAS (KRAS/NRAS) and BRAF mutation status MUST be known. A "we will test later" approach is no longer acceptable.

A. Resectable Metastases (Curative)

With limited liver or lung lesions (oligometastatic disease), cure is the goal.

Approach:

Systemic treatment first: Test biological response with perioperative chemotherapy (FOLFOX).
Local control: Short-course rectal RT (5x5) is preferred; long-course RT delays treatment.
Surgery: Resection using liver-first, simultaneous, or conventional sequencing.

B. Symptomatic Unresectable Disease

Metastases are unresectable and the primary causes bleeding/obstruction.

Palliative strategy:

If not an emergency, as an alternative to a stoma, short-course RT (5x5 Gy) is highly effective for bleeding control.
A colonic stent may be placed.
Start systemic chemotherapy promptly after symptom control.

C. Asymptomatic Unresectable Disease

Widespread metastases; the primary is asymptomatic.

Systemic treatment takes priority:

RT or surgery for the primary tumor: DO NOT perform (no survival benefit—reference: NCCN).
Start Systemic Therapy Directly.
Left Colon (RAS wt): Anti-EGFR (Cetuximab/Panitumumab)
Right Colon / RAS mut: Anti-VEGF (Bevacizumab)

3. Life After Treatment and Follow-up (LARS)

💩 LARS (Low Anterior Resection Syndrome)

Occurs in 50-80% after sphincter-preserving TME surgery and RT. Urgency, frequent bowel movements, and gas leakage.
Management: Loperamide, a fiber-rich diet, pelvic floor physiotherapy, and transanal irrigation.

❤️ Sexual and Urinary Function

Related to pelvic autonomic nerve damage and RT fibrosis. Erectile dysfunction in men and vaginal dryness/dyspareunia in women are common. Discuss these issues actively with patients.

📅 Standard Follow-up (NCCN 2025)

Examination & CEA: Every 3-6 months for the first 2 years.
CT (Chest/Abdomen): Annually for 5 years (every 6 months if high risk).
Colonoscopy: At 1 year after surgery; if clear, after another 3 years.

4. Series Summary: Take-Home Messages

1.
Staging Is Everything: MRF (+) or EMVI (+) on MRI indicates locally advanced disease, requiring TNT.
2.
Molecular Testing Is Mandatory: dMMR patients should not receive TNT/CRT. Dostarlimab immunotherapy is standard for these patients.
3.
TNT Is Established: Completing chemotherapy and radiotherapy before surgery improves survival in high-risk patients. Adjuvant chemotherapy after TNT is generally unnecessary.
4.
Organ Preservation Is Possible: Watch and wait is safe after complete clinical response (cCR) to TNT, but intensive surveillance is essential.

Scientific References (Whole Series):

RAPIDO Trial: "Locoregional failure during and after short-course radiotherapy..." Ann Surg. 2023.
PRODIGE 23: "Total Neoadjuvant Therapy with mFOLFIRINOX..." Lancet Oncol. 2021/2023.
OPRA Trial: "Organ Preservation..." J Clin Oncol. 2022.
NCCN Guidelines: Rectal Cancer Version 1.2025.
ESMO Guidelines: "Rectal Cancer: ESMO Clinical Practice Guidelines." Ann Oncol. 2017/Updated 2024.

Disclaimer: This 4-part guide is a decision-support tool for healthcare professionals based on current literature (2025). Decisions must be individualized in multidisciplinary tumor boards.

Editors: Prof. Dr. Mustafa Özdoğan & Assoc. Prof. Dr. Atakan Demir

Reader comments

Share your comment

Your name and comment are published only after administrator approval. Your email address is never shown to visitors.

Be the first to comment.

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.